Safety and Efficacy of Ceftaroline in Neonates With Staphylococcal Late-onset Sepsis: A Case Series Analysis

Pediatr Infect Dis J. 2023 Oct 1;42(10):888-892. doi: 10.1097/INF.0000000000004023. Epub 2023 Jul 13.

Abstract

Treatment of late-onset neonatal staphylococcal sepsis is sometimes challenging with feared side effects of vancomycin, increasing minimal inhibitory concentrations and questions about catheter management. In case of failure, ceftaroline was administered as a compassionate treatment in 16 infants (gestational age of less than 32 weeks and less than 28 postnatal days), whose first-line treatment failed. We report 11 successes and no severe adverse drug reactions. Larger data are required to confirm these encouraging results.

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Bacteremia* / drug therapy
  • Ceftaroline
  • Humans
  • Infant
  • Infant, Newborn
  • Neonatal Sepsis* / drug therapy
  • Sepsis* / drug therapy
  • Staphylococcal Infections* / drug therapy
  • Vancomycin / adverse effects

Substances

  • Anti-Bacterial Agents
  • Vancomycin